艾迪药业：拟将部分募投项目结项，3649.93万元节余资金永久补充流动资金

Core Viewpoint - The company announced the conclusion of certain fundraising projects and the permanent allocation of surplus funds to working capital [1] Group 1: Project Conclusion - The company held its third board meeting on February 12, 2026, where it approved the conclusion of specific fundraising projects [1] - The projects concluded include the "Phase III clinical and post-marketing research project for Aibond® (Ainovelin tablets)" and the "Phase III/IV clinical project for ACC008" [1] - Both projects have reached the predetermined usable status as of the conclusion date [1] Group 2: Financial Details - As of December 31, 2025, the total surplus fundraising amount from the concluded projects is 36.4993 million yuan [1] - The company plans to permanently allocate the surplus funds to working capital [1] - Following the transfer of surplus funds, the company will cancel the corresponding fundraising special account [1]